Deal Statistics Quarterly, Q3 2005
In this issue, we present another installment of our quarterly review of dealmaking for July-September 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries
You may also be interested in...
The higher the cost of late-stage alliances, the likelier acquisitions are. And that's just what our statistical view of significant acquisitions is showing--the number of $100mm-plus biotech acquisitions has increased dramatically over the last half-decade, including an increasing percentage from Big Pharma.
Like the merger that created Biogen Idec, its new collaboration with PDL is an example of how biotechs can combine to help achieve critical mass. But Biogen Idec still has a lot of heavy lifting to do, especially in one key therapeutic area-oncology.
Bigger generics companies aren't just the generic sector's problem. Giants such as the new Teva will present more formidable challenges to innovators, not just in patent wars but also with proprietary launches, and for a share of drug consumption in developing markets.